At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy
In Brief
A Phase 3 clinical trial evaluating Placebo, E2007 (2 mg), and 3 other interventions for Diabetic Neuropathy. Completed, enrolled 352 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the efficacy and safety of Perampanel in patients with painful diabetic neuropathy.
Study Details
Timeline
Interventions
Placebo tablets, once daily, for 15 weeks (taken orally).
Perampanel, 2 mg once daily, for 15 weeks (taken orally).
Perampanel, 2 mg once daily for three weeks, followed by 4 mg, once daily, for 12 weeks (taken orally).
Perampanel, 2 mg once daily for three weeks, followed by 4 mg once daily, for three weeks and 6 mg, once daily, for nine weeks (taken orally).
Perampanel, 2 mg once daily, for three weeks, followed by 4 mg, once daily for three weeks, 6 mg once daily for three weeks and 8 mg, once daily, for six weeks (taken orally).